Absci (NASDAQ:ABSI) Inc. (NASDAQ: ABSI) is a biotechnology company headquartered in Seattle, Washington, focused on accelerating the discovery and development of protein-based therapeutics. Leveraging its proprietary synthetic biology platform, the company integrates artificial intelligence, machine learning, automation and high-throughput screening to generate novel, high-value proteins with optimized properties for drug development. Absci’s platform is designed to streamline the early stages of discovery, enabling the rapid identification of candidates for diseases ranging from immuno-oncology to infectious and rare diseases.
The core of Absci’s business lies in its proprietary “SeqBuilder” and “Kampala” technologies, which collectively support de novo protein design, cell line engineering and bioprocess optimization. By combining deep-learning algorithms with genome-scale screening and automated lab workflows, Absci can predict protein structures, engineer host cells for enhanced protein expression and scale up manufacturing processes. This end-to-end platform approach aims to reduce the time and cost typically associated with traditional biologics discovery.
Since its founding in 2019, Absci has established collaborative agreements with leading pharmaceutical and biotech firms across North America, Europe and Asia. These partnerships leverage Absci’s platform to co-develop and license novel biologic candidates, reflecting strong industry demand for AI-driven solutions in the competitive drug discovery landscape. The company operates research facilities in Seattle and Shanghai, with additional service capabilities in San Diego and European innovation hubs.
Absci’s leadership team is led by President and Chief Executive Officer Leen Kawas, Ph.D., who brings over two decades of experience in clinical development and biotechnology commercialization. Chief Financial Officer Andrew Blechman oversees the company’s capital strategy and investor relations efforts. Under their guidance, Absci continues to expand its platform capabilities and strategic alliances, positioning the company at the forefront of next-generation protein engineering and therapeutic discovery.
